Pipeline Therapeutics and Janssen enter into a global licensing deal for PIPE-307. The deal is valued up to $1B USD.

Portfolio Company, Ribbon Biolabs featured as one of the top 6 companies making a mark in Synthetic Biology

The generative AI drug company ramps up its internal pipeline and R&D portfolio, tapping into European markets, talent, and tech.